Comprehensive analysis of the expression and significance of CXCLs in human diffuse large B-cell lymphoma

Xiaonan Zhou¹,³, Shizhu Guo¹,³ & Yonghong Shi¹,²

CXCL chemokines (CXCLs) are small cytokines or signal proteins secreted by cells that have been proven to be linked to the occurrence and development of many kinds of cancer. However, the expression and diagnostic and prognostic value of CXCLs in diffuse large B-cell lymphoma (DLBCL) remain to be further studied. We obtained CXCL transcription and survival data of patients with DLBCL from Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), The Cancer Genome Atlas (TCGA), TIMER and cBioPortal databases. R software, STRING and EXCEL were used to process the data. This study discovered that the expression levels of CXCL9-14 in DLBCL were higher than those in normal tissues, while CXCL4, CXCL7 and CXCL8 were lower in tumor than in normal tissues. The expression levels of CXCL2, CXCL10 and CXCL11 were related to tumor stage. CXCL9-14 could be used as an auxiliary molecular marker for the diagnosis of DLBCL. CXCL17 might be a potential prognostic marker of DLBCL.

Chemokines are small molecules of cytokines that can induce chemotactic movement of cells. According to the position of the N-terminal cysteine, chemokines are classified into four major subfamilies: CXC, CC, C and CX3C and CXC, CC, C and CX3C. Their corresponding receptors are CXCR, CCR, CR and CX3CR. The CXC chemokine family is divided into ELR chemokines and non-ELR chemokines based on whether there exists a glutamic acid-leucine-arginine (ELR) functional region in front the first cysteine. CXC members induce chemotactic activity and play a vital role in inflammation and immunity, and are the key inflammatory mediators associated with the presence of chronic inflammatory cells in cancer microenvironment. Meanwhile, they are also targets of carcinogenic pathways. They initially play a prominent role in determining the tumor stromal composition and affect the proliferation and metastasis of cancer cells. Many studies have confirmed that most tumors can autonomously secrete CXC chemokines to promote cell proliferation, growth and metastasis as well as angiogenesis in tumor tissues. The expression of CXCLs is out of control in the cancer of liver, breast and esophageal, lymphoma, and other human malignant tumors.

Lymphoma is a malignancy of the lymphatic system that can be produced by B lymphocytes, T lymphocytes or natural killer (NK) cells at various stages of maturation. Clinic characteristic is painless progressive lymphadenopathy. That can be produced by B lymphocytes, T lymphocytes or natural killer (NK) cells at various stages of maturation. Clinic characteristic is painless progressive lymphadenopathy. It is divided into Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). NHL accounts for 80% of all lymphomas. Diffuse large B-cell lymphoma (DLBCL) is currently recognized the one of the most common forms of NHL.

DLBCL is characterized by diffuse infiltration of medium to large cells with large nucleoli and abundant cytoplasm, which destroys and eliminates the histologic structure of the lymph nodes involved. The tumor cells express B cell markers such as CD19, CD20, CD22, CD45 and CD79. Moreover, CD30 is expressed in approximately 40% of cases and predicts a good prognosis. While immunological and clinical features have limited influence on its prognosis, recent study has focused on the molecular factors. Advances in gene expression profiling have shown that DLBCL contains three different molecular subtypes: (i) germinal center B-cell like (GCBL-like) type, which expresses the molecular markers of normal germinal center B cells and has a good prognosis; and (ii) activated B-cell-like (ABC-like) type, which expresses molecular markers of activated B cells.

¹School of Basic Medical Sciences, Inner Mongolia Medical University, Hohhot 010110, Inner Mongolia Autonomous Region, China. ²Department of Pathology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, China. ³These authors contributed equally: Xiaonan Zhou and Shizhu Guo. ⁴email: 13514815271@163.com
The expression of MYC, BCL6 and BCL2 in DLBCL is associated with disease progression. Recently, TP53 mutation has been increasingly recognized as a feature associated with chemotherapy resistance and low survival. However, the current biomarkers for predicting prognosis still have some limitations. New biomarkers need to be discovered to predict as prognosis and to achieve effectively individualized treatment.

To date, 17 CXC factors have been identified in mammalian cells. They are numbered according to the discovery sequence (CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, and CXCL17). CXCL15 was not involved in this study because there was no information about CXCL15 in the database we used. We hold the view that CXCLs have complex and unique roles in DLBCL. They found that in a considerable number of DLBCL patients, tumor cells constitutively produce the chemokine CXCL8, enabling them to recruit APRIL to induce neutrophils. CXCL8 production affects DNA methylation and acetylation. It mediates neutrophil recruitment and secretes the tumor promoter of APRIL-mediated DLBCL progression. Epstein-Barr virus (EBV) encoded microRNAs (miRNAs) targeting CXCL11 with potent antitumor activity and may be the immuno-modulatory mechanism of DLBCL. CXCL12 and CXCL13 mediate chemotaxis of lymphoma cells. CXCL13 serves as a prognostic and diagnostic biomarker for CNS lymphoma. Abnormal CXCL expression and its relationship with clinicopathological features and prognosis have been partially reported in human DLBCL. To our knowledge, bioinformatics analyses have not been applied to explore the role of CXCLs in DLBCL. With the development of science and technology, as well as the advancement of medical technology, DNA and RNA research has gradually become a principal part of biological and biomedical research. By mining thousands of online gene expression or replication data, we analyzed the expression and potential functions of CXCLs in patients with DLBCL under different factors, providing value for the treatment and prognosis of DLBCL.

Materials and methods

Oncomine analysis. Oncomine (http://www.oncomine.org) is a cancer microarray database and integrated data mining platform designed to facilitate discovery from genome-wide expression analysis. We used Oncomine to analyze the transcriptional level of CXCLs in different tumors. The mRNA expression of CXCLs in tumor tissues was compared with that of normal tissues, and the P-value was obtained by t-test. The limits of the P-value and fold change were 0.01 and 2, respectively.

TCGA dataset. TCGA (The Cancer Genome Atlas) (https://www.cancer.gov/tcga) is a project corporately launched by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) in 2006. It collects clinical data and genomic variation of various human cancers (including subtypes). mRNA expression, miRNA expression, methylation and other data are important data sources for cancer researchers. We used data from the TCGA database DLBC (diffuse large B-cell lymphoma) project and R (version 4.1.1) (Basic R package) to analyze CXCL expression in tumor stages and judged the diagnostic value of CXCLs in patients with DLBCL. P-value < 0.05 were considered significant.

GEPIA dataset. GEPIA (http://gepia.cancer-pku.cn/) is a newly developed interactive web server for analyzing the RNA sequencing expression of a large number of tumors and normal samples from the TCGA and GTEx projects using a standard processing pipeline. Moreover, GEPIA provides customizable functions, such as tumor/normal differential expression analysis, patient survival analysis, and similar gene detection. We, to explore the expression of CXCLs in DLBCL and the prognostic value of the mRNA level of CXCLs in DLBCL patients. We also used EXCEL drawing diagrams to show the correlations between CXCLs, statistical method: Spearman, P-value < 0.05 were considered significant.

cBioPortal. cBioPortal for Cancer Genomics (cBioPortal, https://www.cbioportal.org/) contains data from 126 tumor genomic studies, including large tumor research projects such as TCGA and ICGC, covering 28,000 samples, as well as phenotypic information such as clinical prognosis. We used the cBioPortal online tool to analyze the changes in CXCLs.

STRING. STRING (https://string-db.org/, version 11.5) can search online for known protein interactions. We used STRING to build the network for CXCLs and frequently altered neighboring genes.

R. R is a free software environment for statistical computing and graphics. We used R (version 4.1.1) (http://www.r-project.org) (pROC package Ggplot2 package) to analyze the diagnostic value of CXCLs in patients with DLBCL. The closer the AUC is to 1, the better the diagnostic effect is. It has low accuracy when AUC is between 0.5 and 0.7. AUC has a certain accuracy between 0.7 and 0.9. While AUC above 0.9 has high accuracy. We used R (ggplot2 package and clusterprofiler package) to explore the correction between different CXCLs in DLBCL and predicted the functions of CXCLs and the genes significantly related to the alterations of CXCLs by analyzing conduct Kyoto encyclopedia of genes and genomes (KEGG) enrichment results, adjusted P<0.05 was deemed as a meaningful pathway.

TIMER. TIMER (https://cistrome.shinyapps.io/timer/, version 2.0) is a web server for comprehensive analysis of Tumor-Infiltrating Immune Cells. We obtained the relationship between CXCL expression and...
immune infiltration through TIMER2.0 database. We also used EXCEL drawing diagrams to show the correlations between them, statistical method: Spearman, \( P \)-value < 0.05 were considered significant.

Data availability. The data used to support the findings of this study are openly available from TCGA database. Citing TCGA in Publications and Presentations was originally published by the National Cancer Institute. The results <published or shown> here are in whole or partly based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.

Consent for publication. All authors agreed to publish.

Results

Transcription levels of CXCLs in patients with DLBCL. Seventeen CXCL factors were found in mammalian cells. We used the Oncomine database to compare CXCL transcription levels in a variety of cancer samples with normal samples. CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, and CXCL14 expression in the tissue adjacent to carcinoma was significantly different (Fig. 1). We also summarized the transcription of 16 chemokine families in DLBCL from eight databases. The changes in the mRNA expression levels of CXCL1, CXCL3-8 and CXCL17 in lymphoma patients were not particularly significant (\( P > 0.05 \)) (Table 1). Next, we focused on the expression of CXCLs in samples of DLBCL. In Compagno Lymphoma Statistics, CXCL2 was overexpressed in DLBCL versus normal tissue with a fold change of 2.544 consistent with Alizadeh Lymphoma Statistics.

In Alizadeh Lymphoma Statistics, CXCL9 was found to be more highly expressed in DLBCL supported by Storz, Rosenwald, Compagno, Brune, and Basso (Table 1). Rosenwald multicancer statistics showed that CXCL10 was increased in DLBCL (fold change = 5.390) compared to normal samples. The same results were reported by Compagno, Basso, and Storz (Table 1). In Basso's dataset and Compagno's dataset, CXCL11 had a significant increase in DLBCL. CXCL12 was also highly expressed in DLBCL than in normal samples.

Alizadeh's dataset, Basso's dataset, and Compagno's dataset all indicated that CXCL13 was more highly expressed in DLBCL (Table 1). In Compagno Lymphoma Statistics, CXCL14 was overexpressed in DLBCL versus normal tissue with a fold change of 5.168. CXCL16 was overexpressed with a fold change of 3.107 (Table 1).

Relationship between CXCL mRNA levels and clinicopathological parameters in patients with DLBCL. Using the GEPIA (Interactive Analysis of Gene Expression Profiles) dataset, we compared the mRNA expression of CXCL factors in DLBCL with normal tissue. The findings revealed that the expression levels of CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14 were higher than normal tissue, the expression levels of CXCL14, CXCL7 and CXCL8 were lower than that of normal tissue (\( P < 0.05 \)) (Fig. 2). We also used data from the TCGA database DLBC project to analyze CXCL expression in DLBCL.
results indicated that the expression of CXCLs was related to tumor stage. There was a significant relationship with tumor stage in the group of CXCL2, CXCL10 and CXCL11 (P < 0.05). In contrast, the expression of CXCL1, CXCL3-9, CXCL12-14 and CXCL16-17 had no significant relationship with tumor stage (Table 2).

The diagnostic value of CXCLs in patients with DLBCL. We further investigated the role of CXCLs in the diagnostic value of patients with DLBCL. We used R (pROC package, GGplot2 package) to analyze and visualize the data. The results displayed that the prediction ability was high in CXCL9 (AUC = 0.997), CXCL10 (AUC = 0.965), CXCL11 (AUC = 1.000), CXCL12 (AUC = 0.992), CXCL13 (AUC = 0.997) and CXCL14 (AUC = 0.942) and low in CXCL1 (AUC = 0.533), CXCL4 (AUC = 0.684), CXCL5 (AUC = 0.511), CXCL6 (AUC = 0.629), CXCL8 (AUC = 0.678) and CXCL17 (AUC = 0.519), and was a certain degree of accuracy in CXCL2 (AUC = 0.769), CXCL4 (AUC = 0.837) and CXCL7 (AUC = 0.849). In addition, CXCL16 had poor predictive power and diagnostic efficacy (AUC = 0.483) (shown in Fig. 3).

Association of the increased or decreased CXCL mRNA expression and improved prognosis in patients with DLBCL. We further investigated the role of CXCLs in the survival of patients with DLBCL. We used the GEPIA database to analyze the association of CXCL mRNA levels with survival in patients with DLBCL by using public datasets and used R (survminer package and survival package) to draw Kaplan–Meier curves. Kaplan–Meier curves and logarithmic rank tests showed that increased mRNA levels of CXCL9-14 and decreased CXCL4 and CXCL7-8 mRNA levels were not significantly associated with overall survival (OS) or disease-free survival (DFS) in all patients with DLBCL (P > 0.05). Higher CXCL17 mRNA levels were associated with prognosis in patients with DLBCL because of higher OS (P < 0.05) (Fig. 4A,B).

Functional enrichment analysis of CXCL factors and adjacent genes in patients with DLBCL. We used the cBioPortal online tool to analyze the changes in CXCLs. CXCLs were altered in 135 patients with DLBCL (3.6%). Changes were detected in approximately five samples (Fig. 5A). We also analyzed CXCL mRNA sequencing data by R (ggplot2 package) and calculated the correlation between them and used EXCEL to complete the drawing (Fig. 5B). The correlations between CXCLs were shown in Fig. 5B. We also used STRING to construct a network of CXCLs and related adjacent genes. The results showed that the inflammatory cytokine IL16 and colony stimulating factor CSF3 were closely related to CXCLs (Fig. 5C).

KEGG analysis can identify the functional related pathways of CXCLs and neighboring genes. By KEGG analysis, we identified 10 pathways in reference to CXCLs function in DLBCL. Among these pathways, hsa04650

| CXCL     | Fold change | P-value  | t-test  | Source and/or reference                      |
|----------|-------------|----------|---------|----------------------------------------------|
| CXCL2    | 2.544       | 1.73E−6  | 5.101   | Compagno lymphoma statistics                  |
|          | 3.005       | 0.015    | 3.853   | Alizadeh lymphoma statistics                  |
| CXCL9    | 9.957       | 0.002    | 5.659   | Alizadeh lymphoma statistics                  |
|          | 24.803      | 6.37E−4  | 5.642   | Storz lymphoma statistics                     |
|          | 17.389      | 3.86E−16 | 14.862  | Rosenwald multicancer statistics              |
|          | 19.907      | 1.44E−8  | 7.017   | Basso lymphoma statistics                     |
|          | 54.026      | 6.12E−31 | 23.643  | Compagno lymphoma statistics                  |
|          | 19.134      | 3.27E−5  | 6.522   | Brune lymphoma statistics                     |
| CXCL10   | 5.390       | 8.61E−9  | 7.348   | Rosenwald multicancer statistics              |
|          | 8.586       | 9.08E−7  | 5.484   | Basso lymphoma statistics                     |
|          | 22.362      | 8.76E−27 | 19.120  | Compagno lymphoma statistics                  |
|          | 7.699       | 0.001    | 5.144   | Storz lymphoma statistics                     |
| CXCL11   | 14.345      | 1.38E−19 | 15.464  | Compagno lymphoma statistics                  |
|          | 15.820      | 3.09E−8  | 6.825   | Basso lymphoma statistics                     |
| CXCL12   | 2.438       | 1.03E−5  | 5.044   | Alizadeh lymphoma statistics                  |
|          | 3.254       | 1.66E−6  | 6.258   | Rosenwald multicancer statistics              |
|          | 3.485       | 1.74E−15 | 11.315  | Compagno lymphoma statistics                  |
| CXCL13   | 10.710      | 0.024    | 3.108   | Alizadeh lymphoma statistics                  |
|          | 10.064      | 4.36E−9  | 6.802   | Basso lymphoma statistics                     |
|          | 17.816      | 1.09E−12 | 9.726   | Compagno lymphoma statistics                  |
| CXCL14   | 5.168       | 2.59E−11 | 8.320   | Compagno lymphoma statistics                  |
|          | 3.107       | 2.39E−18 | 12.583  | Compagno lymphoma statistics                  |

Table 1. Significant changes in CXCL expression at the transcription level between DLBCL and normal tissues (Oncomine DATABASE).
Figure 2. Expression of CXCLs in DLBCL (GEPIA, http://geopia.cancer-pku.cn/). The expression of CXCLs in DLBCL (box plot) (note: red represents tumor tissue and gray represents normal tissue).
Correlation between CXCL expression and immune infiltration. Specifically, as shown in Fig. 7, CXCL1 expression was negatively correlated with CD4 + B cells and T cells. The expression of CXCL2 and CXCL5 had the same relationship with immune cells as CXCL1. CXCL3 expression was negatively correlated with CD4 + B cells and T cells; in addition, CXCL3 expression was positively correlated with neutrophils. The expression of CXCL6-8 was negatively correlated with CD4 + T cells. CXCL9-11 expressions were negatively correlated with B cells and macrophages; furthermore, CXCL9-11 expressions were appreciably positively correlated with CD8 + T cells, neutrophils and myeloid dendritic cells. CXCL12 expression was positively correlated with CD8 + T cells, neutrophils and myeloid dendritic cells but negatively correlated with CD8 + T cells. CXCL16 expression was positively correlated with the infiltration of several immune cell types, including B cells, CD8 + T cells, neutrophils and myeloid dendritic cells. Additionally, it was negatively correlated with CD4 + T cells. There was no marked infiltration with CXCL4 and CXCL17 in DLBCL.

Discussion
CXCLs were dysregulated in a variety of cancers. The role of CXCLs in the development, diagnosis and prognosis of several cancers has been partially established. The data we obtained showed more insight into the tumorigenesis and pathogenesis of DLBCL (Fig. 6A–D).

Table 2. Correlation between CXCL expression and tumor stage in DLBCL (TCGA). Significant values are in bold.

| Clinical stage, n (%) | Stage I | Stage II | Stage III | Stage IV | p |
|----------------------|---------|----------|-----------|----------|---|
| Characteristic       |         |          |           |          |   |
| CXCL1                | High expression 2 (4.8%) | 9 (21.4%) | 2 (4.8%) | 7 (16.7%) | 0.544 |
|                      | Low expression 6 (14.3%) | 8 (19%)  | 3 (7.1%) | 5 (11.9%) |   |
| CXCL2                | High expression 0 (0%)  | 10 (23.8%) | 3 (7.1%) | 7 (16.7%) | 0.019 |
|                      | Low expression 8 (19%)   | 7 (16.7%) | 2 (4.8%) | 5 (11.9%) |   |
| CXCL3                | High expression 1 (2.4%) | 9 (21.4%) | 4 (9.5%) | 7 (16.7%) | 0.088 |
|                      | Low expression 7 (16.7%) | 8 (19%)  | 1 (2.4%) | 5 (11.9%) |   |
| CXCL4                | High expression 3 (7.1%) | 8 (19%)  | 3 (7.1%) | 6 (14.3%) | 0.917 |
|                      | Low expression 9 (21.4%) | 8 (19%)  | 2 (4.8%) | 6 (14.3%) |   |
| CXCL5                | High expression 2 (4.8%) | 9 (21.4%) | 3 (7.1%) | 6 (14.3%) | 0.580 |
|                      | Low expression 6 (14.3%) | 8 (19%)  | 2 (4.8%) | 6 (14.3%) |   |
| CXCL6                | High expression 3 (7.1%) | 9 (21.4%) | 2 (4.8%) | 6 (14.3%) | 0.917 |
|                      | Low expression 5 (11.9%) | 8 (19%)  | 3 (7.1%) | 6 (14.3%) |   |
| CXCL7                | High expression 5 (11.9%) | 9 (21.4%) | 2 (4.8%) | 5 (11.9%) | 0.845 |
|                      | Low expression 3 (7.1%)  | 8 (19%)  | 3 (7.1%) | 7 (16.7%) |   |
| CXCL8                | High expression 4 (9.5%) | 8 (19%)  | 4 (9.5%) | 4 (9.5%) | 0.387 |
|                      | Low expression 4 (9.5%)  | 9 (21.4%) | 1 (2.4%) | 8 (19%)  |   |
| CXCL9                | High expression 2 (4.8%) | 8 (19%)  | 3 (7.1%) | 7 (16.7%) | 0.554 |
|                      | Low expression 6 (14.3%) | 9 (21.4%) | 2 (4.8%) | 5 (11.9%) |   |
| CXCL10               | High expression 1 (2.4%) | 7 (16.7%) | 5 (11.9%) | 7 (16.7%) | 0.015 |
|                      | Low expression 7 (16.7%) | 10 (23.8%) | 0 (0%)  | 5 (11.9%) |   |
| CXCL11               | High expression 1 (2.4%) | 8 (19%)  | 5 (11.9%) | 6 (14.3%) | 0.021 |
|                      | Low expression 7 (16.7%) | 9 (21.4%) | 0 (0%)  | 6 (14.3%) |   |
| CXCL12               | High expression 4 (9.5%) | 6 (14.3%) | 3 (7.1%) | 6 (14.3%) | 0.742 |
|                      | Low expression 4 (9.5%)  | 11 (26.2%) | 2 (4.8%) | 6 (14.3%) |   |
| CXCL13               | High expression 5 (11.9%) | 6 (14.3%) | 3 (7.1%) | 4 (9.5%) | 0.485 |
|                      | Low expression 3 (7.1%)  | 11 (26.2%) | 2 (4.8%) | 8 (19%)  |   |
| CXCL14               | High expression 4 (9.5%) | 6 (14.3%) | 4 (9.5%) | 6 (14.3%) | 0.379 |
|                      | Low expression 4 (9.5%)  | 11 (26.2%) | 1 (2.4%) | 6 (14.3%) |   |
| CXCL16               | High expression 2 (4.8%) | 10 (23.8%) | 2 (4.8%) | 7 (16.7%) | 0.434 |
|                      | Low expression 6 (14.3%) | 7 (16.7%) | 3 (7.1%) | 5 (11.9%) |   |
| CXCL17               | High expression 4 (9.5%) | 9 (21.4%) | 3 (7.1%) | 4 (9.5%) | 0.690 |
|                      | Low expression 4 (9.5%)  | 8 (19%)  | 2 (4.8%) | 8 (19%)  |   |
There are few studies on the expression of CXCLs in lymphoma except CXCL8 and CXCL11 in DLBCL\(^{10,11}\). Other CXCL factors have not been studied. The pathogenesis of CXCLs in DLBCL requires inspiration from other types of lymphoma and other cancers.

We have several hypotheses about the mechanisms of CXCLs and tumorigenesis. First, Epstein-Barr virus (EBV) positive DLBCL is a different entity. EBV can downregulate the expression of CXCL1 and transform human B lymphocytes by promoting the cell cycle and mitosis, inhibiting apoptosis, hindering host immune function and cytokine secretion to promote the production of tumors\(^8\). Taking CXCL1 as an example, we speculate that CXCLs can promote the production of EBV + DLBCL through the EBV infection-NF-κB pathway. Second, the expression of CXCLs can also be influenced by hypoxia inducible factor α (HIF-1α) in the tumor microenvironment. Hypoxia is a common feature of tumor microenvironment. Hypoxia leads to an increase in HIF-α.

---

**Figure 3.** Correlation between CXCL expression and diagnosis in DLBCL (TCGA, R version 4.1.1, http://www.r-project.org).
through the NF-κB pathway, which leads to a change in CXCL expression levels. CXCLs facilitate angiogenesis and other pathways to promote tumor cells to obtain different proliferation and metastasis potentials. Third, AP-1 family transcription factors regulate a variety of cellular activities in classical Hodgkin's lymphoma and
Whether CXCLs and their associated genes also promote tumor proliferation, inhibit apoptosis, and evade host immune responses through the AP-1 and NF-κB pathways remains unclear. In this study, the Oncomine dataset and TCGA dataset showed no difference in CXCL1 expression levels between DLBCL patients and normal samples. ROC curves showed that CXCL1 had a low predictive value for DLBCL. Using the Kaplan–Meier curve, which means that CXCL1 expression was not associated with the prognosis of patients with DLBCL.

Similarly, CXCL2 expression levels in DLBCL patients were not statistically significant in tumor tissues and normal samples. ROC curves showed that CXCL2 had a certain predictive value for DLBCL. CXCL2 expression was not associated with the prognosis of patients with DLBCL by Kaplan–Meier curve.

The expression levels of CXCL9-14 in tumor samples were higher than those in normal samples. Besides, CXCL2 and CXCL10-11 were related to the tumor stage. The expression of the CXCL family was not related to the prognosis except CXCL17. From this, we speculate that CXCL2 and CXCL17 may play an important role in the pathogenesis development of DLBCL.

Moreover, CXCLs and their closely related genes could induce and promote tumorigenesis in many ways. For example, natural killer cell-mediated cytotoxicity, the IL-17 signaling pathway and cytokine-cytokine receptor interactions are mentioned in the text. They might be related to apoptosis. Fas, IFN-γ, COX2, CSF, TRAIL and so on can induce or promote apoptosis (KEGG). We can further explore the expression of CXCLs and their mechanism of apoptosis in DLBCL.

The development of various tumors is highly related to the physiological state of the tumor microenvironment (TME). With the continuous understanding and deepening of the tumor immune microenvironment, it has great development potential in the prediction and guidance of immunotherapy. According to the TIMER2.0 database, our results showed that the expression of CXCLs was positively correlated with the expression of tumor-infiltrating immune cells in the TME. CXCLs played an important role in TME. All components of the TME support tumor cells by producing growth factors, chemokines and so on, thus promoting tumor proliferation and metastasis.

**Conclusion**

Overall, our study systematically analyzed the expression of CXCLs in DLBCL and its diagnostic and prognostic value, which provided a theoretical basis for further understanding the molecular biological and clinical characteristics of DLBCL. Clinical stages suggested that the high expression of CXCL2, CXCL10 and CXCL11 might leave a deep impression on the occurrence and development. The high expression of CXCL9-14 could also be used...
Figure 6. Kyoto Gene and Genome Encyclopedia (KEGG) pathways of CXCLs and genes significantly associated with CXCLs. (A) The functions of CXCLs and genes significantly associated with CXCLs were predicted by the analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG); (B) natural killer cell mediated cytotoxicity; (C) IL-17 signaling pathway and (D) cytokine–cytokine receptor interaction regulated by the CXCLs alteration in DLBCL were shown.
Figure 7. Correlation between CXCL expression and immune infiltration in DLBCL (EXCEL, version Microsoft Office Mondo 2016, https://office.microsoft.com/excel) (note: red indicates that the two parameters were positively correlated, and blue indicates that the two parameters were negatively correlated. The darker the color, the stronger the correlation).

as an auxiliary molecular marker for its diagnosis. In addition, our results also suggest that transcribed CXCL17 may be a potential prognostic marker for improving survival and prognostic accuracy in patients with DLBCL.

Data availability
Materials and data from the study were available.

Received: 19 October 2021; Accepted: 7 February 2022
Published online: 18 February 2022

References
1. Łukaszewicz-Zając, M., Pączek, S. & Mroczko, B. The significance of chemokine CXCL-8 in esophageal carcinoma. Arch. Med. Sci. (AMS) 16, 475–480 (2020).
2. Mollica Poeta, V., Massara, M., Capucetti, A. & Bonecchi, R. Chemokines and chemokine receptors: New targets for cancer immunotherapy. Front Immunol 10, 379 (2019).
3. Wu, S., Singh, S., Varney, M. L., Kindle, S. & Singh, R. K. Modulation of CXCL-8 expression in human melanoma cells regulates tumor growth, angiogenesis, invasion, and metastasis. Cancer Med 1, 306–317 (2012).
4. Hwang, S. et al. Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets. Hepatology (Baltimore, MD) 72, 412–429 (2020).
5. Łukaszewicz-Zając, M., Pączek, S., Muszyński, P., Kozlowski, M. & Mroczko, B. Comparison between clinical significance of serum CXCL-8 and classical tumor markers in oesophageal cancer (OC) patients. Clin. Exp. Med. 19, 191–199 (2019).
6. Abrahamsson, A., Rzepecka, A. & Dabrosin, C. Equal pro-inflammatory profiles of CCLs, CXCLs, and matrix metalloproteinases in the extracellular microenvironment in vivo in human dense breast tissue and breast cancer. Front. Immunol. 8, 1994 (2017).
7. Ishikki, Y. & Melnick, A. Epigenetic mechanisms of therapy resistance in diffuse large B cell lymphoma (DLBCL). Curr. Cancer Drug Targets 21, 274–282 (2021).
8. Castillo, J. J. et al. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. Am. J. Hematol. 93, 953–962 (2018).
9. Liu, Y. & Barta, S. K. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am. J. Hematol. 94, 604–616 (2019).
10. Manfoi, B. et al. CXCL-8/LIF produced by diffuse large B-cell lymphomas recruits neutrophils expressing a proliferation-inducing ligand APRIL. Can. Res. 77, 1097–1107 (2017).
11. Xia, T. et al. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Can. Res. 68, 1436–1442 (2008).
12. Rubenstein, J. L. et al. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood 121, 4740–4748 (2013).
13. Rhodes, D. R. et al. Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neo- plasia (New York, N.Y.) 9, 166–180 (2007).
14. Tomczak, K., Czerwińska, P. & Wiznerowicz, M. The Cancer Genome Atlas (TCGA): An immeasurable source of knowledge. Contemp. Oncol. (Polozn, Poland) 19, A68–77 (2015).
15. Tang, Z. et al. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45, W98-w102 (2017).
16. Cerami, E. et al. The Cancer Systems Biology Portal: A platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
17. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the Cancer Systems Biology Portal. Sci. Signal. 6, l1 (2013).
18. Szklarczyk, D. et al. The STRING database in 2021: Customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 49, D605-d612 (2021).
19. Chan, B. K. C. Data analysis using R programming. Adv. Exp. Med. Biol. 1082, 47–122 (2018).
20. Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).
21. Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947–1951 (2019).
22. Kanehisa, M., Furumichi, M., Sato, Y., Ishiguro-Watanabe, M. & Tanabe, M. KEGG: Integrating viruses and cellular organisms. Nucleic Acids Res. 49, D545-d551 (2021).
23. Li, T. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48, W509-w514 (2020).
24. Li, T. et al. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Can. Res. 77, e108–e110 (2017).
25. Li, B. et al. Comprehensive analyses of tumor immunity: Implications for cancer immunotherapy. Genome Biol. 17, 174 (2016).
26. Compagno, M. et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459, 717–721 (2009).
27. Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000).
28. Storz, M. N. et al. Gene expression profiles of cutaneous B cell lymphoma. J. Invest. Dermatol. 120, 865–870 (2003).
29. Rosenwald, A. et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J. Exp. Med. 194, 1639–1647 (2001).
30. Brune, V. et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J. Exp. Med. 205, 2251–2268 (2008).
31. Basso, K. et al. Reverse engineering of regulatory networks in human B cells. Nat. Genet. 37, 382–390 (2005).
32. Chen, X., Chen, R., Jin, R. & Huang, Z. The role of CXCL chemokine family in the development and progression of gastric cancer. Int. J. Clin. Exp. Pathol. 13, 484–492 (2020).
33. Pażzek, S. et al. CXCL-8 in preoperative colorectal cancer patients: significance for diagnosis and cancer progression. Int. J. Mol. Sci. 21, 34 (2020).
34. Guo, L., Situ, H. L., Wang, Z. Y., Lin, Y. & Chen, Q. J. Mechanism of Jinxong granule in inhibiting the invasion of breast cancer cells by the CXCL-1–CXCR2/CCL20 pathway. J. Biol. Regul. Homeost. Agents 34, 969–976 (2020).
35. Dwivedi, A., Kiely, P. A. & Hoey, D. A. Mechanically stimulated osteocytes promote the proliferation and migration of breast cancer cells via a potential CXCL1/2 mechanism. Biochem. Biophys. Res. Commun. 534, 14–20 (2021).
36. Xu, G. et al. Correlation between chemokine CXCL-12 and its receptor CXCR4 expression is associated with clinical prognosis of gastric cancer. Clin. Lab. 66, 4 (2020).
37. Zhang, G. et al. CXCL-13 regulates resistance to 5-fluorouracil in colorectal cancer. Cancer Res. Treat. 52, 622–633 (2020).
38. Dai, Y. et al. Screening and functional analysis of differentially expressed genes in ERV-transformed lymphoblasts. Virol. J. 9, 77 (2012).
39. Korbecki, J. et al. The effect of hypoxia on the expression of CXC chemokines and CXC chemokine receptors—a review of literature. Int. J. Mol. Sci. 22, 843 (2021).
40. Wu, Z., Nicoll, M. & Ingham, R. J. AP-1 family transcription factors: A diverse family of proteins that regulate varied cellular activities in classical Hodgkin lymphoma and ALK+ ALCCL. Exp. Hematol. Oncol. 10, 4 (2021).
41. Fang, C. et al. IFN-γ-induced ER stress impairs autophagy and triggers apoptosis in lung cancer cells. Oncoimmunology 10, 1962591 (2021).
42. Mao, M. G. et al. Fas/FasL of pacific cod mediated apoptosis. Dev. Comp. Immunol. 119, 104022 (2021).
43. Razeghian, E. et al. Harnessing TRAIL-induced apoptosis pathway for cancer immunotherapy and associated challenges. Front. Immunol. 12, 699746 (2021).
44. Xu, Y. et al. Impact of knockdown LincRNA-Cox2 on apoptosis of macrophage infected with Bacillus Calmette-Guérin. Mol. Immunol. 130, 85–95 (2021).
45. Zhang, M. et al. Cytoplasmic M-CSF facilitates apoptosis resistance by inhibiting the HIF-1α/BNP3/Bax signalling pathway in MCF-7 cells. Oncol. Rep. 41, 1807–1816 (2019).
46. Roma-Rodrigues, C., Mendes, R., Baptista, P. V. & Fernandes, A. R. Targeting tumor microenvironment for cancer therapy. Int. J. Mol. Sci. 20, 840 (2019).
47. Bunnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541–550 (2018).

Acknowledgements
The authors thank Inner Mongolia Medical University for their support.

Author contributions
X.Z. and S.G. are equally contributed to this study and responsible for the material search, data sorting and content writing as well as content supplement. Y.S. is responsible for the supplementation and modification of the content. In addition, Y.S. is the corresponding author.

Funding
There is no funding projects.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to Y.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022, corrected publication 2022